Elanco Animal Health Inc
Elanco Animal Health (ELAN) reported Q2 2026 revenue of $1.368B, up 8% organic constant currency, and adjusted EBITDA of $288M (+21%). Adjusted EPS was $0.34 (+31%). Management raised 2026 revenue guidance to $5.09B-$5.14B and adjusted EPS to $1.10-$1.16, citing innovation sales led by Zenrelia and Credelio Quattro.
Elanco Animal Health (NYSE: ELAN) shares rose about 3.4% after Q2 2026 results beat expectations and management raised guidance. Elanco reported revenue of $1.37B vs $1.31B expected and adjusted EPS of $0.34 vs $0.27, with 2026 guidance of EPS $1.10–$1.16 and revenue $5.09B–$5.14B. Analysts including KeyBanc, UBS and Citi raised targets to $30–$34.
VanHimbergen Robert M (EVP and CFO) purchased 4,200 shares of Elanco Animal Health Inc (ELAN) at $23.08 on 2026-08-07.
Over the past 7 days, alphai's AI scored 3 news stories mentioning ELAN (Elanco Animal Health Inc). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent ELAN coverage spans earnings, insider activity and market movers.
In the last 30 days, ELAN insiders filed 2 SEC Form 4 transactions — 2 purchases ($334K) and no sales. The most active reporter was Herendeen Paul with 1 filing.
Raised FY and Q3 guidance, with margin expansion tied to Elanco Ascend and strong innovation revenue momentum (Zenrelia, Credelio Quattro).
Beat-and-raise quarter plus higher 2026 EPS and revenue targets is a direct catalyst for ELAN’s near-term momentum and sentiment.
Insider open-market buying by the CFO is a modest positive signal, but it is not a fundamental catalyst by itself.
This is a routine insider open-market buy with no 10b5-1 plan, but it is not a fundamental catalyst by itself.
Guidance and innovation-target raise suggest improving mix and productivity, supporting a constructive earnings outlook.
alphai scores every news story that mentions ELAN with an AI model for sentiment and relevance, and aggregates insider trades from Elanco Animal Health Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Elanco Animal Health (ELAN) reported Q2 2026 revenue of $1.368B, up 8% organic constant currency, and adjusted EBITDA of $288M (+21%). Adjusted EPS was $0.34 (+31%). Management raised 2026 revenue guidance to $5.09B-$5.14B and adjusted EPS to $1.10-$1.16, citing innovation sales led by Zenrelia and Credelio Quattro.
6 min readElanco Animal Health (NYSE: ELAN) shares rose about 3.4% after Q2 2026 results beat expectations and management raised guidance. Elanco reported revenue of $1.37B vs $1.31B expected and adjusted EPS of $0.34 vs $0.27, with 2026 guidance of EPS $1.10–$1.16 and revenue $5.09B–$5.14B. Analysts including KeyBanc, UBS and Citi raised targets to $30–$34.
4 min readVanHimbergen Robert M (EVP and CFO) purchased 4,200 shares of Elanco Animal Health Inc (ELAN) at $23.08 on 2026-08-07.
1 min readHerendeen Paul purchased 10,000 shares of Elanco Animal Health Inc (ELAN) at $23.68 ($0.24M total) on 2026-08-07.
2 min readElanco Animal Health (NYSE:ELAN) reported Q2 updates on pet and farm results. Credelio Quattro gained market share, with product in over half of U.S. clinics. Early Befrena demand was described as soft-launched in May, with supply constrained until early 2027. AdTab international OTC parasiticides sales rose over 30%. Elanco raised 2026 innovation revenue target to about $1.25B and guided FY revenue $5.09B-$5.14B, adjusted EBITDA $1.01B-$1.035B, adjusted EPS $1.10-$1.16.
7 min readElanco Animal Health (NYSE:ELAN) reported adjusted earnings of 34 cents per share, above the 27-cent consensus. Q2 sales rose 10% to $1.368B. Pet Health revenue grew 12% to $718M. The company raised FY2026 guidance: adjusted EPS to $1.10-$1.16 and sales to $5.09-$5.14B.
6 min readS&P 500 futures rose about 0.4% to near 7,800, a new all-time high, after strong earnings and record S&P 500 call buying. Nasdaq-100 futures lagged as AMD and SpaceX results disappointed. Nvidia gained on an exclusive partnership to build AI infrastructure on NVIDIA platforms. Several other stocks moved on guidance or earnings, including ANET, SHOP, CVS, and FLUT.
7 min readElanco Animal Health (ELAN) reported Q2 results and issued Q3 guidance, expecting adjusted EPS of $0.19 to $0.22 on revenue of $1.195B to $1.220B, with 5% to 7% organic constant-currency growth. For FY2026, it raised outlook to adjusted EPS $1.10 to $1.16 on revenue $5.09B to $5.14B, up from prior $1.03 to $1.09 on $5.01B to $5.085B. Shares rose to $27.37.
2 min readElanco Animal Health (ELAN) rose about 8.9% in pre-open after reporting Q2 2026 results ahead of estimates. Adjusted EPS was $0.34 vs $0.27 consensus, and revenue was $1.37B vs $1.31B, with organic constant-currency growth of 8%. Adjusted EBITDA was $288M, net leverage improved to 3.1x, and full-year guidance was lifted, pushing the stock to a new 52-week high.
3 min readElanco (NYSE:ELAN) reported Q2 CY2026 revenue of $1.37 billion, up 10.2% year on year and 4.2% above Wall Street estimates, according to the company. Non-GAAP EPS was $0.34, 26.5% above consensus. Next-quarter revenue guidance was $1.21 billion at the midpoint. The article also notes a stock rise to $27.16.
4 min read
